ArticleBMC microbiology2025
Prevalence of katG and inhA mutations associated with isoniazid resistance in Mycobacterium tuberculosis clinical isolates in Cameroon.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Routine Molecular Surveillance of Drug-Resistant Tuberculosis: Translating Mutation Proxies into Clinical Governance Intelligence in Rural Eastern Cape.Healthcare (Basel, Switzerland) · 2026Article
- Pattern and prevalence of rifampicin and isoniazid-resistant tuberculosis using genotype MTBDRMicrobiology spectrum · 2026Article
- Predictive Analysis of Drug-Resistant Tuberculosis: Integrating Molecular Markers, Clinical Governance, and Community-Engaged Education in Rural South Africa.Diseases (Basel, Switzerland) · 2026Article
- Multidrug-Resistant Tuberculosis in Rural Eastern Cape, South Africa: Clinical, Bacteriological, and Programmatic Predictors of Poor Treatment Outcomes.Microorganisms · 2026Article
- Genetic surveillance of first- and second-line drug-resistant isolates of Mycobacterium tuberculosis in Peru.PloS one · 2026Article
- Machine learning-based analysis of drug resistance mutations in Mycobacterium tuberculosis.PloS one · 2026Article
- Uncovering the structural impact of KatG Ser315 mutations in Mycobacterium tuberculosis via cryo-EM.Protein science : a publication of the Protein Society · 2026Article
- Comparison of Pyrazinamide with Isoniazid for Their Effects on the Heme Biosynthetic Pathway in Mouse Liver.Metabolites · 2025Article
- Genetic diversity, drug resistance, and transmission patterns of tuberculosis based on whole-genome sequencing in Almaty, Kazakhstan.Frontiers in microbiology · 2025Article
- Host range expansion ofFrontiers in microbiology · 2025Article
- Progress of anti-tuberculosis drug targets and novel therapeutic strategies.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe acquisition of isoniazid (INH) resistance is alarming, considering its importance as a key drug that forms the core of multidrug treatment regimens for tuberculosis (TB). Genetic mutations in the katG and inhA promoter regions play crucial roles in INH resistance, but their prevalence varies geographically. This study aimed to identify the most common mutations in the katG and inhA genes in INH-resistant (INH-R) Mycobacterium tuberculosis (MTB) clinical isolates in Cameroon. The research also explored the relationships between these mutations and patients' demographics (age, sex, and sample type).
methodsWe conducted a retrospective cross-sectional laboratory-based study on 500 INH-R isolates (with or without resistance to other first-line drugs) at the National Tuberculosis Reference Laboratory (NTRL) in Cameroon between January 2014 and December 2020. GenoType MTBDRplus assay was performed on the retrieved isolates and the frequency of katG and inhA mutations were calculated. Chi-square tests were utilized to assess the associations between these mutations and patients' age, sex and sample type.
resultsA total of 410 (85.8%) culture-positive MTB isolates were analyzed, with a male-to-female ratio of 228 (55.6%) to 182 (44.4%) and an average age of 36.3 ± 13.4 years. Mutations in the katG and inhA genes were detected in 354 (86.3%) of cases, while 56 (13.7%) showed no mutations. Among the INH-R isolates, mutations in katG, inhA, and dual katG and inhA genes were present in 247 (60.2%), 76 (18.5%), and 31 (7.6%) isolates, respectively. Our analysis revealed significant associations between mutation prevalence and patient characteristics.
conclusionThis study reaffirmed the importance of the katG S315T substitution as a key indicator of INH resistance, with the inhA C-15T mutation providing additional support. However, a notable proportion of isoniazid-resistant isolates did not exhibit these mutations, underscoring the need to comprehend resistance mechanisms. Given that these mechanisms are strongly associated with varying levels of INH resistance, it is crucial that TB management strategies incorporate genetic profiling alongside patient demographics to optimize treatment outcomes and enhance control measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.